Overview

Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient

Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether conversion from cyclosporine, a calcineurin inhibitor (CI) to sirolimus (SRL) results in improved long-term renal function without a negative impact on safety or immunosuppressive efficacy, and to further examine the potential of SRL to reduce the severity and/or progression of chronic allograft nephropathy (CAN).
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Calcineurin Inhibitors
Cyclosporine
Cyclosporins
Everolimus
Sirolimus
Tacrolimus